Pharmaceutical Companies

Novo Nordisk Eli Lilly Pfizer AstraZeneca Johnson & Johnson Lobbying Moderna Market Strategies Gilead Sciences Bankruptcy

Trump Administration Begins Enforcing Prescription Drug Price Controls

HHS and CMS initiate implementation of most-favored-nation pricing order as questions about legal authority and innovation impacts persist.

Trump Orders U.S. Drug Prices Tied to Lowest OECD Rates, Sparking Concerns Over Global Impact

Over 100 Women in England Secure Compensation for Vaginal Mesh Complications

Surge in GLP-1 Drugs for Weight Loss Sparks Concerns Over Diabetes Treatment

Ozempic Shows Promise Beyond Diabetes Treatment

Zealand Pharma's Petrelintide Shows Promising Results in Early Weight Loss Trial

Cencora Data Breach Exposes Sensitive Medical Information of US Patients

US House Advances Bill Targeting Chinese Biotech Firms

First US Lawsuit Filed Against AstraZeneca by Vaccine Trial Participant

Bernie Sanders Targets Novo Nordisk Over High U.S. Drug Prices

Eli Lilly Faces Zepbound Shortage, Impacting Weight Loss and Diabetes Patients

Moderna's Cancer Vaccine Shows Promising Results in Trial with Merck's Keytruda

FDA Approves Merck's Winrevair for Rare Lung Disease

Corcept Therapeutics Executives Acquire Stock Options

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

AstraZeneca Projects Strong Growth in 2024 Despite COVID-19 Sales Dip

Eli Lilly's Weight-Loss Drug Zepbound and Diabetes Treatment Mounjaro Drive Record Earnings

Novartis Acquires MorphoSys for $2.9 Billion, Expanding Cancer Drug Portfolio

Novo Nordisk Expands Production Capacity with $16.5 Billion Catalent Acquisition

Bristol Myers Reports Strong Q4 Earnings, Exceeds Expectations